PTCH1 and cancer: HH pathway has been investigated for potential therapeutic antagonists as a strategy for cancer treatment, although the focus is limited to ligand-dependent effectors such as Patched 1 (PTCH1) and Smoothened (SMO); Frizzled class receptor [11,12].